Peptide-mimetic treatment ofPseudomonas aeruginosain a mouse model of respiratory infection

Abstract

The rise of drug resistance has become a global crisis, with >1 million deaths due to resistant bacterial infections each year.Pseudomonas aeruginosa,in particular, remains a serious problem with limited solutions due to complex resistance mechanisms that now lead to more than 32,000 multidrug-resistant (MDR) infections and over 2,000 deaths annually. While the emergence of resistant bacteria has become concerningly common, identification of useful new drug classes has been limited over the past 40+ years. We found that a potential novel therapeutic, the peptide-mimetic TM5, is effective at killingP. aeruginosaand displays sufficiently low toxicity for mammalian cells to allow for use in treatment of infections. Interestingly, TM5 killsP. aeruginosamore rapidly than traditional antibiotics, within 30-60 minutesin vitro, and is effective against a range of clinical isolates.In vivo, TM5 significantly reduced bacterial load in the lungs within 24 hours compared to untreated mice and demonstrated few adverse effects. Taken together, these observations suggest that TM5 shows promise as an alternative therapy for MDRP. aeruginosarespiratory infections.